HVCN1

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funders: National Institute of Neurological Disorders and Stroke and 1 more

Animals1

Effects

Apoptosis

upin mice1

1 study

HVCN1 increases apoptosis in mice.
“Hv1 deletion enhanced chromatin remodeling, epigenetic and Wnt signaling, while suppressing NF-κB-driven inflammation and oxidative stress-induced apoptosis.”
Animalsafter spinal cord injuryspinal cordmales
Hv1 Upregulation Worsens Spinal, Spleen, and Lung Molecular Pathology and Impairs Locomotion after Spinal Cord Injury in Aged Male Mice
Aging and disease15 Dec 2025

Latest

1 in 12 months

Aging and Disease16 Dec

Hv1 Upregulation Worsens Spinal, Spleen, and Lung Molecular Pathology and Impairs Locomotion after Spinal Cord Injury in Aged Male Mice

Experiments in miceLung

Paper

HVCN1

Effects

Latest

Hv1 Upregulation Worsens Spinal, Spleen, and Lung Molecular Pathology and Impairs Locomotion after Spinal Cord Injury in Aged Male Mice

Related